RxDoctor Payments Data

Robert Baker

Surgical · Rancho Mirage, CANPI 1568425239

Payments from drug & device makers

$2,541in general payments, 2019–2025

Across 74 payments — averaging $34.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AbbVie$610
  • SPR Therapeutics, Inc$446
  • Painteq LLC$217
  • Collegium Pharmaceutical, Inc.$90
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$45
  • plus $93 from 4 others

What the payments were for

  • Travel & lodging$46518%
  • Food & beverage$2,07782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,541 in reported general payments places this provider in the 80th percentile of 729 surgical providers in California.

See all surgical providers in California

Medicare billing

Part B allowed, 2024
$83,666
Medicare patients
220
Services billed
1,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl44$36,732
BelbucaBuprenorphine Hcl38$28,037
Lidocaine124$17,581
Diclofenac Sodium236$15,394
MovantikNaloxegol Oxalate36$14,218
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen445$13,035
ZtlidoLidocaine19$12,842
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen243$11,121
LinzessLinaclotide20$10,720
SymproicNaldemedine Tosylate21$10,084
Buprenorphine23$6,909
Gabapentin419$6,040
Oxycodone Hcl176$4,660
Morphine Sulfate ErMorphine Sulfate110$3,126
Naloxone Hcl36$2,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$90$28,03738 claims
Scilex Pharmaceuticals Inc.Ztlido$21$12,84219 claims
AbbVieLinzess$610$10,72020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 surgical providers in California.

Other surgical in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →